Endo International plc (ENDP, ENL.TO) reported a second quarter loss from continuing operations of $91 million compared to profit from continuing operations of $41 million, prior year. Loss per share from continuing operations was $0.49 compared to profit of $0.25. Adjusted earnings per share from continuing operations was $1.08, and total adjusted earnings per share was $1.20, for the quarter.
On average, 14 analysts polled by Thomson Reuters expected the company to report profit per share of $1.02 for the quarter. Analysts' estimates typically exclude special items.
Revenues were $735 million, a 24 percent increase compared to second quarter 2014 revenues of $593 million, including new product revenue from 2014 and 2015 strategic M&A transactions. Analysts expected revenue of $727.45 million for the quarter.
For the full twelve months ended December 31, 2015, at current exchange rates, Endo affirmed revenue and adjusted EPS guidance from continuing operations, prior to the impact of the pending close of the acquisition of Par Pharmaceutical and related financing activities.
The company expects 2015 total revenue to be between $2.90 billion and $3.00 billion. Earnings per share from continuing operations is now expected to be between $1.42 and $1.62 compared to $1.70 and $1.90 previously; and adjusted EPS from continuing operations is expected to be between $4.40 and $4.60. Analysts expect the company to report earnings per share of $4.53 on revenue of $2.99 billion.
For comments and feedback contact: editorial@rttnews.com
Business News